Surveys

Guidelines for Surveys of Membership

Approval is required to advertise surveys to the ARA Membership. The procedure for Surveys of the Membership can be found here.
Please advise:

  • What are the broad aims of the survey?
  • Why are you doing the survey i.e. is it a trainee research project?
  • The target audience ie rheumatologists, trainees, non-medical members?
  • What are you trying to achieve?
  • Does the study have ethics approval? If so, please supply the HREC committee and the relevant ethics approval.
  • Is it endorsed by a member of the ARA or one of its committees or groups?
  • The time period of the survey ie when does it finish?
  • If you are planning for the responses to be anonymised, then it is best not to include the postcode as one of the questions. Due to the small number of ARA members, inclusion of a postcode will likely allow identification even if names are not included within the survey response.


Please enclose a copy of the survey, the research protocol and ethics approval with your application and send to ara@rheumatology.org.au.

Development of Clinical Care Standard for Giant Cell Arteritis (GCA) — National Survey

https://redcap.link/gca_clinical_care_standards
 

The Australian Rheumatology Association is developing Australia's first Clinical Care Standards for Giant Cell Arteritis (GCA) and is seeking feedback from healthcare professionals and consumers on draft quality statements. The survey takes approximately 15-30 minutes and is open until 9 July 2026 (with a possible extension to 6 August 2026). Click here to complete the survey. Estimated completion time: 15-30 minutes.

Principal Investigator: Dr Charlotte Woollard, Project Coordinator, GCA Clinical Care Standards, Australian Rheumatology Association
Contact: Charlotte.Woollard@health.wa.gov.au

Survey Closes: 9 July 2026 (with a possible extension to 6 August 2026)

Date Posted: 1 June 2026

Multiple Advanced Therapies in Inflammatory Diseases, the MAT study

Click here to complete the survey.

Do you have patients on or ≥2 advanced immunosuppressive therapies (eg biological agents) concurrently that are not typically used in combination?

Researchers from the University of Sydney are looking to assess the important and emerging area of outcomes of these patients, via an online de-identified registry. All data is stored securely and in the strictest of confidence, and the study has been granted Human Research Ethics Committee approval.

Please follow this link for the database to fill out patient details or receive further details. The survey takes 5-10 minutes (per patient). Any clinician who fills ≥10 patients will be offered co-authorship on the academic output.

Many thanks in advance for your time

Dr John Chetwood (john.chetwood@health.nsw.gov.au)
On behalf of the
The Multiple Advanced Therapies Research Team 

Survey Closes: 29 May 2026

Date Posted: 4 January 2024